Pfizer Teams With Eight Boston-Area Research Institutions In $100MM Tie-Up
This article was originally published in The Pink Sheet Daily
Executive Summary
The collaboration is the third in its localized Centers for Therapeutic Innovation project, intended to nudge academics toward commercial projects.
You may also be interested in...
Deals Of The Week: GSK’s Stealth Move To The Coasts
The British pharma opens new innovation centers in San Diego and Cambridge, Mass., to connect with those academic, business and venture investment communities. Also, Roche and Biogen Idec make moves in neurodegenerative disease, Retrophin makes two deals for different forms of the same drug, and GSK makes the latest alliance in the cancer immunology arena.
Pfizer’s CTI Shows Tangible Signs Of Progress In Its Junior Year
Pfizer’s Centers for Therapeutic Innovation program has grown in less than three years to include 24 academic partners. First drug candidate to emerge from the research model is expected to enter the clinic this year, and Pfizer’s investment in CTI has grown.
AZ Restructures, But Will Changes Sideline Plans To Accelerate R&D?
AstraZeneca unveiled an R&D restructuring March 18 that will consolidate research to three locations and reduce headcount by 1,600, but the company will have to be dogged in its effort to relocate key employees if it is to ensure the changes don’t disrupt its broader goal of accelerating the pace of R&D.